Page 251 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
EGFR and PIK3CA mutations in lung cancer patients

BRAF, ALK, and cMET genetic alterations in 1440 Sardinian doi: 10.7150/ijbs.22955
patients with lung adenocarcinoma. BMC Pulm Med. 13. Pretelli G, Spagnolo CC, Ciappina G, Santarpia M, Pasello G.
2019;19(1):209. Overview on therapeutic options in uncommon EGFR
doi: 10.1186/s12890-019-0964-x mutant non-small cell lung cancer (NSCLC): New lights for
an unmet medical need. Int J Mol Sci. 2023;24(10):8878.
4. Travis WD, Brambilla E, Nicholson AG, et al. The 2015
World Health Organization classification of lung tumors: doi: 10.3390/ijms24108878
Impact of genetic, clinical and radiologic advances since the 14. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling
2004 classification. J Thorac Oncol. 2015;10(9):1243-1260. network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
doi: 10.1097/JTO.0000000000000630 doi: 10.1038/35052073
5. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non- 15. Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting
small cell lung cancer: Epidemiology, risk factors, treatment, HER2 in non-small-cell lung cancer (NSCLC): A glimpse
and survivorship. Mayo Clin Proc. 2008;83(5):584-594. of hope? An updated review on therapeutic strategies
doi: 10.4065/83.5.584 in NSCLC harbouring HER2 alterations. ESMO Open.
2021;6(5):100260.
6. Sha X, Gong G, Qiu Q, Duan J, Li D, Yin Y. Identifying
pathological subtypes of non-small-cell lung cancer by doi: 10.1016/j.esmoop.2021.100260
using the radiomic features of 18 F-fluorodeoxyglucose 16. Loeffler E, Ancel J, Dalstein V, Deslée G, Polette M,
positron emission computed tomography. Transl Cancer Nawrocki-Raby B. HER2 alterations in non-small cell lung
Res. 2019;8(5):1741-1749. cancer: Biologico-clinical consequences and interest in
doi: 10.21037/tcr.2019.08.20 therapeutic strategies. Life (Basel). 2023;14(1):64.
doi: 10.3390/life14010064
7. EL Founini Y, Guessous F, Dehbi H, et al. First insight into
the mutational landscape of BRAF and KRAS genes in lung 17. Pillai RN, Behera M, Berry LD, et al. HER2 mutations in
cancer patients from Morocco. Curr Pharmacogenomics Pers lung adenocarcinomas: A report from the lung cancer
Med. 2024;Vol 22. mutation consortium. Cancer. 2017;123(21):4099-4105.
doi: 10.2174/0118756921347352241112105112 doi: 10.1002/cncr.30869
8. Restrepo JC, Martínez Guevara D, Pareja López A, 18. Rubin E, Shan KS, Dalal S, et al. Molecular targeting of the
Montenegro Palacios JF, Liscano Y. Identification and human epidermal growth factor receptor-2 (HER2) genes
application of emerging biomarkers in treatment of non- across various cancers. Int J Mol Sci. 2024;25(2):1064.
small-cell lung cancer: Systematic review. Cancers (Basel). doi: 10.3390/ijms25021064
2024;16(13):2338.
19. Zhao L, Vogt PK. Hot-spot mutations in p110alpha
doi: 10.3390/cancers16132338 of phosphatidylinositol 3-kinase (pI3K): Differential
9. Hu H, Zhu J, Zhong Y, et al. PIK3CA mutation confers interactions with the regulatory subunit p85 and with RAS.
resistance to chemotherapy in triple-negative breast cancer Cell Cycle. 2010;9(3):596-600.
by inhibiting apoptosis and activating the PI3K/AKT/mTOR doi: 10.4161/cc.9.3.10599
signaling pathway. Ann Transl Med. 2021;9(5):410.
20. Martín Martorell P, Huerta M, Compañ Quilis A, et al.
doi: 10.21037/atm-21-698 Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations
10. Liu X, Mei W, Zhang P, Zeng C. PIK3CA mutation as an and ALK rearrangement in a comprehensive cohort of 326
acquired resistance driver to EGFR-TKIs in non-small consecutive Spanish nonsquamous NSCLC patients. Clin
cell lung cancer: Clinical challenges and opportunities. Lung Cancer. 2017;18(6):e395-e402.
Pharmacol Res. 2024;202:107123. doi: 10.1016/j.cllc.2017.04.006
doi: 10.1016/j.phrs.2024.107123 21. Tsao MS, Nicholson AG, Maleszewski JJ, Marx A, Travis WD.
11. Moasser MM. The oncogene HER2: Its signaling and Introduction to 2021 WHO classification of thoracic tumors.
transforming functions and its role in human cancer J Thorac Oncol. 2022;17(1):e1-e4.
pathogenesis. Oncogene. 2007;26(45):6469-6487. doi: 10.1016/j.jtho.2021.09.017
doi: 10.1038/sj.onc.1210477 22. Sambrook J, Fritsch ER, Maniatis T. Molecular Cloning:
nd
12. Yang Z, Tam KY. Combination strategies using EGFR-TKi in A Laboratory Manual. 2 ed. Cold Spring Harbor, NY: Cold
NSCLC therapy: Learning from the gap between pre-clinical Spring Harbor Laboratory Press; 1989.
results and clinical outcomes. Int J Biol Sci. 2018;14(2): 23. Lemine Sow M, El Yacoubi H, Moukafih B, et al. Frequency
204-216. and types of EGFR mutations in Moroccan patients with

Volume 9 Issue 1 (2025) 243 doi: 10.36922/ejmo.7111